Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They got what they wanted.
"We are short" No surprise.lol
The company's under attack because the data is that good. No reason to sic the dogs otherwise.
Somebody's buying them up that's for sure. Way to many for retail to handle.
Notice the constant reference of lawsuit. Enough said. Dr Missling has the data and repeated primary and secondary endpoints were met.
From the conference call-
ADAS-Cog - meaningful improvement in cognition
ADCS-ADL- meaningful improvement in function
A-273 was reported safe.
Agree. This could cause a monumental monetary shift in treating Alzheimer's. The word will ultimately get out, people and caregivers will want it. Change will come.
ADAS-Cog scores meaningful improvement in cognition
ADCS-ADL scores meaningful improvement in function
So yes people improved.
A-273 was reported safe.
Blarcamesine now!
I think an important note to Dr Missling et al is that A-273, if approved, the cost would not be shifted to medicare because as a pill it would be covered under ones drug plan. Due to Lecanemab being an infusion plus the associated outpatient costs it was put under medicare billing which set in premium increases for all those on medicare.
Short fodder. I'm buying and holding strong.
Top line results put shorts in a jam but good.
All those in the ABSSSI trial who received B got a single dose infusion and went home healed of their affliction. Dapto takes 7 infusions. Also there's the likelihood that B's MOA will not create bacterial resistance. Looking for further anti-fungal reporting plus a nasal formula update.
Thank you! Much appreciated.
Me too as they say. I see this as a great opportunity. We have been de risked since the last time we were at these levels.
Dr Missling is a competent CEO and with the excellent results as what we have (by his leadership I may add) can get A-273 approved for Alzheimer, PDD, Retts, FragileX. So far so good. BP value will likely be effected when approval comes but the plus side and what's important is people are helped:)
Ah gotcha yes a bedtime dosing.
I heard it as SAP statistical analysis protocol. My take is they followed the planned test study and found A-273 checked all the boxes. Starts@44:35 Got to listen carefully though.
https://video.wixstatic.com/video/79bcf7_6566f1d485d2424eadf745c64a05ff7a/480p/mp4/file.mp4
Good post! This is where the rubber meets the road. A very real threat in BP's future value. We get excellent trial results and it's an all out effort to tank the company. Hoping for some honest analysts.
Yes BP's definitely know now. We have a lot of new bears here. Biogen got bested good.
We were just handed superior Alzheimer's results with more indications to come. I consider this a long term buy and hold. I've been adding again as of late.
Anavex will likely take market share of other companies in this space and that's a rub. My take away this morning is if your marketing an infusion drug your in trouble.
That was bad. Hopefully he is still well. The elderly are precious to their families.
I imagine reading a book, playing piano and painting. Dr Missling can likely give more in-depth report now that trial has finished. I hope A-273 gives a lot of people long term healing. Good stuff.
Exactly, here's what they all saw and it's as crisp and clear as a cold December morning. Huge news.
ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE
Yeah just look at donepizil. Early approval.
We have a winner!! A-273 may just set the new standard of care.
I believe they are afraid of a cure as funding would dwindle. Anavex as we have seen has some uphill to go but positive news trumps all. Big organizational donors get all the accolades.
Alzheimer's is a very hard nut to crack so I'll go out on a limb and say longs are quite pleased with results. That's really all that matters.
Your trying too hard. Trial was and is very successful against a really tough disease. Read the 8k.
I believe it's not the drop as much as the rise up that has them worried. Next week could be fun.
They are majoring in minors. The data 45% @ 48 weeks beats Biogen's mab and that's what matters. And then there's the shorts.
I believe a week ago you posted secondary endpoints would not be met so there's that. Primary AND Secondary have been met per 8k. Biogen is verrry nervous today imo.
Yes. Three more indications to power it up!
It's the shorts who have their math wrong.
They are trying to instill doubt. The power of A-273 is too great.
Anavex ushers in a new standard of care! What a headline.
I believe the timeline for a FDA response is 45 days.
Real analysts will soon pick up on today's great news.
AF by another name.lol